BioSpace News Archive

Drug Development

Humanetics Corporation Announces Results from Phase 1 Trial of BIO 300 Oral Powder

Humanetics Corporation (Humanetics) announced today that it has completed a phase 1 trial of the Company’s medical countermeasure for acute radiation syndrome (ARS), BIO 300 Oral Powder (NCT04650555).

September 22, 2021
·
3 min read
Drug Development

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating Disorders

The trial is being conducted with Jennifer Miller, M.D., from the University of Florida and will evaluate the Company’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy.

September 22, 2021
·
5 min read
Study Shows Heru’s Automated Visual Field Testing Platform Delivers Strong Correlation to Humphrey Field Analyzer

A report by Heru Inc., the innovative vision diagnostics and augmentation leader, indicates that visual field test results from its wearable platform, re:Vive by Heru, are strongly correlated to the ZEISS Humphrey Field Analyzer (HFA).

September 22, 2021
·
3 min read
BioMidwest

SHINE’s new name highlights technology competencies and multiple phase opportunities

SHINE Medical Technologies LLC announced that the company has changed its name to SHINE Technologies LLC.

September 22, 2021
·
4 min read
Drug Development

Viewpoint Molecular Targeting(R) Announces Publication of Preclinical Data of VMT01 in Peer-Reviewed Journal, “Cancers”

Viewpoint Molecular Targeting, Inc. announced the publication of VMT01 preclinical data in an article titled, Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma1 in the peer-reviewed journal Cancers.

September 22, 2021
·
4 min read
Business

Scipher Medicine Welcomes John Strumbos as Chief Financial Officer

Scipher Medicine, a precision immunology company matching patients with their most effective therapies, announced the appointment of John Strumbos, Ph.D., MBA as Chief Financial Officer.

September 22, 2021
·
2 min read
Drug Development

First Patient Randomized in Tarsier Pharma’s TRS4VISION Phase-III Clinical Trial in Patients with Active Non-Infectious Anterior Uveitis Including Patients with Uveitic Glaucoma

Tarsier Pharma today announced the initiation of its Phase 3 trial TRS4VISION by randomizing the first patient for treatment.

September 22, 2021
·
2 min read
Vertex’s Supplement to a New Drug Submission for KALYDECO (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada

Vertex Pharmaceuticals Incorporated today announced its Supplement to a New Drug Submission for Pr KALYDECO ® (ivacaftor) has been accepted for priority review by Health Canada for the treatment of cystic fibrosis

September 22, 2021
·
4 min read
Spectrum Pharmaceuticals to Participate in 2021 Cantor Virtual Global Healthcare Conference

Spectrum Pharmaceuticals today announced that management will participate in the 2021 Cantor Virtual Global Healthcare Conference. A fireside chat is scheduled for Wednesday, September 29, 2021, at 1:20 p.m. ET.

September 22, 2021
·
3 min read
Lone Star Bio

DJO® Expands Active, Adaptive Healing Offerings with Introduction of MedShape® DynaNail Hybrid™

DJO, a subsidiary of Colfax Corporation and a leading global provider of medical technologies to get and keep people moving, announced the launch of the MedShape® DynaNail Hybrid™ Fusion System.

September 22, 2021
·
3 min read